Comparative Pharmacology
Head-to-head clinical analysis: ARYMO ER versus OPANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYMO ER versus OPANA.
ARYMO ER vs OPANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYMO ER (morphine sulfate) is a full opioid agonist that binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception. It also activates descending inhibitory pathways.
Mu-opioid receptor agonist; produces analgesia by binding to opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception.
15 mg to 30 mg orally every 12 hours; titrate to effect; maximum 60 mg per dose.
5-20 mg orally every 4-6 hours as needed for pain; extended-release tablets: 5 mg orally every 12 hours, titrated up to 20 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 11–13 hours in healthy adults. This extended half-life compared to immediate-release morphine (2–4 hours) allows for once-daily dosing. In elderly or hepatic/renal impairment, half-life may be prolonged up to 22 hours.
Terminal elimination half-life is 11-16 hours (mean 14 hours) in adults; prolonged in hepatic impairment (up to 30 hours) and elderly.
Primarily renal (90%), with approximately 10% excreted unchanged in urine; the remainder as glucuronide conjugates (morphine-3-glucuronide, morphine-6-glucuronide) and minor metabolites. Biliary/fecal excretion accounts for <10%.
Primarily renal (approximately 90% as conjugated metabolites, 10% unchanged); biliary/fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic